Suppr超能文献

雌激素受体α(ESR1)基因扩增在乳腺癌中很常见。

Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.

作者信息

Holst Frederik, Stahl Phillip R, Ruiz Christian, Hellwinkel Olaf, Jehan Zeenath, Wendland Marc, Lebeau Annette, Terracciano Luigi, Al-Kuraya Khawla, Jänicke Fritz, Sauter Guido, Simon Ronald

机构信息

Department of Pathology, University Medical Center Hamburg Eppendorf, D-20246 Hamburg, Germany.

出版信息

Nat Genet. 2007 May;39(5):655-60. doi: 10.1038/ng2006. Epub 2007 Apr 8.

Abstract

Using an Affymetrix 10K SNP array to screen for gene copy number changes in breast cancer, we detected a single-gene amplification of the ESR1 gene, which encodes estrogen receptor alpha, at 6q25. A subsequent tissue microarray analysis of more than 2,000 clinical breast cancer samples showed ESR1 amplification in 20.6% of breast cancers. Ninety-nine percent of tumors with ESR1 amplification showed estrogen receptor protein overexpression, compared with 66.6% cancers without ESR1 amplification (P < 0.0001). In 175 women who had received adjuvant tamoxifen monotherapy, survival was significantly longer for women with cancer with ESR1 amplification than for women with estrogen receptor-expressing cancers without ESR1 amplification (P = 0.023). Notably, we also found ESR1 amplification in benign and precancerous breast diseases, suggesting that ESR1 amplification may be a common mechanism in proliferative breast disease and a very early genetic alteration in a large subset of breast cancers.

摘要

我们使用Affymetrix 10K SNP基因芯片筛选乳腺癌中的基因拷贝数变化,在6q25处检测到编码雌激素受体α的ESR1基因的单基因扩增。随后对2000多个临床乳腺癌样本进行的组织芯片分析显示,20.6%的乳腺癌存在ESR1扩增。与无ESR1扩增的癌症患者中66.6%的比例相比,99%的ESR1扩增肿瘤显示雌激素受体蛋白过表达(P<0.0001)。在175名接受辅助他莫昔芬单药治疗的女性中,ESR1扩增的癌症患者的生存期明显长于无ESR1扩增的雌激素受体表达阳性癌症患者(P = 0.023)。值得注意的是,我们还在乳腺良性和癌前疾病中发现了ESR1扩增,这表明ESR1扩增可能是乳腺增生性疾病中的常见机制,也是大部分乳腺癌中非常早期的基因改变。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验